Johnson & Johnson (JNJ) Buy, Sell or Hold

Johnson & Johnson (JNJ)

228.45

+0.06 (0.03%)

as of Jun 18, 2026, 11:54:36 pm Market Open.

496 watching

COMMENT

A fine, long-term story but shares were hammered today when the CEO announced aggressive numbers that the street doubted. Nearly all healthcare stocks sold off, too.

TOP PICK

So many things going for it. New CEO, really trying to put more emphasis on the medical business. One of 2 companies in the world with a AAA credit rating. Resurgence in medical procedures. A play on demographics, Covid rebound, and higher margin businesses. Yield is 2.54%. (Analysts’ price target is $182.15)

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Oct 20/22, Up 7.4%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with JNJ is progressing well. To remain disciplined, we recommend trailing up the stop to $166 at this time.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly JNJ is a defensive holding that is trading below peer valuation (23x earnings vs 36x for peers). The company is preparing to spin off its consumer division in favour of more investment into its pharmaceutical and medical device divisions. It is reportedly making progress on a ground breaking ulcerative colitis treatment. We recommend placing a stop at $150, looking to achieve $190 -- upside over 15%. Yield 2.7% (Analysts’ price target is $187.82)

HOLD

In process of spinning off consumer products, could lead to value accretion. At lower end of 52-week range, growth has slowed down from historic levels and this gives him pause. Middle valuation among older line pharma. "Blue chip" of pharma industry. He's OK with it, but his pick for portfolios is ELV.

BUY

Continue to like the business. Spinoff of consumer business is a good move. Established business with good prospects. Is a good defensive name(high dividend) for long term investors. Will continue to hold.

BUY

Healthcare is defensive because you have constant demand for these products and services. Investors should have exposure in this uncertain economy. Her pick here is JNJ, given its strong balance sheet. They offer pharmaceuticals, medical devices and consumer products, so are diversified. Aging demographics will fuel demand.

BUY

JNJ vs. PFE Coin flip. Both are stable for the long run. PFE is slightly cheaper right now.

PAST TOP PICK

(A Top Pick Sep 16/21, Up 3%) A solid return, considering the year we had. 60 years of consecutive dividend increases. Look at the spinout that's coming. Growth should accelerate. Long term story, not a trade story.

BUY

Great company with limited downside, but more possible upside because of its pending break-up. JNJ will get into regular generic drugs which offers growth.

TOP PICK

She likes healthcare for being a defensive growth sector. JNJ's balance sheet is very strong, so lots of money to buy companies and grow. They spend a lot on R&D. 70% of revenues come from products that rank #1 or 2. 25% of revenues are from products launched within 5 years. Boasts powerful brands across all segments. Their pharma division is doing well, comprising 55% of company revenues. Drugs coming off-patent can be replaced by 14 drugs totaling a potential $5 billion in sales. They pay a 2.7% dividend they has been increasing for 60 straight years. (Analysts’ price target is $186.88)

BUY

Has a great balance sheet and is smart by breaking itself up.

TOP PICK

Giant in pharma. Also medical and consumer. Likes pharma, as it's large and has scale. Patents are more insulated from cliffs than its peers. Well staggered expiry dates, diversified components. Spinoff of consumer division should unlock value. Outperformed S&P 500 in 5/6 of the last bear markets. Undemanding 17x earnings. Yield is 2.66%. (Analysts’ price target is $188.56)

BUY

It reports Tuesday a transitional quarter. JNJ is breaking into a slower-growth consumer products business, and a higher-growth pharma and medical device division. He expects good numbers even in the interim now.

BUY

Healthcare is defensive name in current market. Upcoming spinoffs planned of business units will change profile of company. Long history of rising dividends and solid financial metrics. Is a good company to hold for the long term. Current share price is attractive.

Showing 46 to 60 of 583 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Most Recent Experts

Stockchase Insights

5i Research

Brian Acker, CA

Acker Finley Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

Barometer Capital Management

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Johnson & Johnson (JNJ)